Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Wednesday, November 11, 2020,...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the appointment of Richard Vile, Ph.D., to its Scientific Advisory Board (SAB). Dr....
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Tuesday, August 4, 2020, at...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) (TSX: ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, ...
CALGARY and SAN DIEGO, CA, Dec. 27, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech...
Proposed phase 3 study design is found acceptable and can form the basis of a Marketing Authorization Application (MAA) Feedback continues to support ...
Dr. Matt Coffey, Oncolytics' President & Chief Executive Officer, to present on the clinical progress of using reovirus as an immuno-oncology viral...
CALGARY and SAN DIEGO, Nov. 30, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company ...
Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone...
CALGARY, and SAN DIEGO, CA, Nov. 8, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech...
CALGARY and SAN DIEGO, CA, Nov. 2, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech...
Presenting clinical data of REOLYSIN® in metastatic breast cancer and the Company's strategic objectives CALGARY and SAN DIEGO, Oct. 11, 2017...
Dr. Andres Gutierrez, Oncolytics' Chief Medical Officer, to present on the clinical progress and robust safety findings of using reovirus as an...
Outcome supports focus on HR+/HER2- patient group that reported an effective doubling of median overall survival from 10.8 to 21.0 months CALGARY and ...
CALGARY and SAN DIEGO, Sept. 14, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech...
Additional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2-...
CALGARY and SAN DIEGO, CA, Aug. 3, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced...
CALGARY, AB and SAN DIEGO, CA, Aug. 1, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) will present...
Announces end-of-phase 2 meeting with the U.S. Food and Drug Administration CALGARY and SAN DIEGO, July 26, 2017 /PRNewswire/ - Oncolytics Biotech®...
Responsible for Global Partnering and Business Development CALGARY and SAN DIEGO, June 29, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX: ONC)...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.